Ipamorelin: GHSR-1a selectivity and the cortisol-sparing story
Ipamorelin is the cleanest tool compound in the growth-hormone secretagogue family. It works at a different receptor than sermorelin/CJC/tesamorelin (GHSR-1a, the ghrelin receptor, rather than the GHRH-R), and the literature explicitly compares it to older secretagogues on a single dimension: receptor selectivity. The story is unusually well-defined for a research peptide and worth understanding before designing a study.
The receptor
Ipamorelin is a pentapeptide — H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — designed as a synthetic ghrelin mimetic. The target is the growth hormone secretagogue receptor 1a (GHSR-1a), a class-A G-protein-coupled receptor coupled to Gαq → phospholipase C → IP₃ / DAG / Ca²⁺ signaling. This is a fundamentally different transduction pathway than the GHRH-R's Gαs / cAMP signaling, and the somatotrope integrates input from both receptors when deciding when to release GH[1].
The physiology matters: in normal pituitary signaling, GHRH and ghrelin (the natural GHSR-1a ligand) work synergistically. GHRH drives transcription of new GH; ghrelin/GHSR-1a drives release of stored GH. Pharmacologically, combining a GHRH-R agonist (sermorelin / CJC / tesamorelin) with a GHSR-1a agonist (ipamorelin) produces a larger GH pulse than either alone — which is the basis for the "GHRH + secretagogue" protocols documented in physiology textbooks[2].
The selectivity story
The reason ipamorelin specifically entered the development pipeline is its receptor selectivity. The Raun 1998 paper in European Journal of Endocrinology compared ipamorelin's effect on GH release versus its effect on cortisol, ACTH, and prolactin — three other hormones older secretagogues (notably GHRP-6 and hexarelin) elevated as off-target effects via the corticotrope axis[3].
The clean result: ipamorelin produced a robust GH response at doses where cortisol, ACTH, and prolactin remained at baseline. The follow-on Andersen 2001 paper confirmed this selectivity in a head-to-head comparison with GHRP-6, showing ipamorelin's GH:cortisol response ratio was approximately 4× higher than the older compound's[4]. The mechanism for the selectivity is not fully resolved — likely a combination of GHSR-1a subtype binding profile and biased signaling — but the phenotype is well-replicated.
"The selectivity finding is the entire reason ipamorelin matters. GHRP-6 produces a larger GH spike but drags cortisol and prolactin with it. Ipamorelin engineers around the off-target axis. For any research study where HPA-axis confound matters, ipamorelin is the cleaner tool."
Why this matters for study design
If your protocol is studying GH release or IGF-1 elevation specifically, the cortisol confound from older secretagogues is a methodological problem — elevated cortisol independently affects glucose handling, lean mass, and inflammation endpoints. Ipamorelin removes that confound. For protocols specifically looking at GHSR-1a engagement without HPA-axis activation, it is the standard tool.
For protocols looking for maximum GH release without concern for selectivity, GHRP-6 or hexarelin produces a larger acute response. The trade-off is honest.
Combination with GHRH analogs
The most-studied combination in the secretagogue literature is GHRH-R agonist plus GHSR-1a agonist administered together. The two pathways converge at the somatotrope and produce a GH pulse 2–3× the sum of either alone. This is documented at the cellular level (the Mathieson 2010 in vitro work) and at the systemic level in healthy human pharmacology studies[5].
In the published in-vitro literature on this combination — sermorelin + ipamorelin, or CJC-no-DAC + ipamorelin — the synergistic growth-hormone response is reported to appear when both peptide classes are present concurrently rather than sequentially. Mathieson 2010 attributes the effect to simultaneous engagement of the GHRH-R and GHSR-1a pathways at the somatotrope; where the two classes are present sequentially rather than together, the same work reports an additive rather than synergistic response[5].
What the literature does NOT show
- No registered clinical indication. Ipamorelin's clinical development stalled after the early-2000s pharmacology work. There is no FDA-approved indication.
- Selectivity isn't perfect. The cortisol-sparing finding is dose-dependent. At sufficiently high doses, ipamorelin loses some of its selectivity.
- Long-term receptor desensitization data is thin. Most published work is acute pharmacology. Whether GHSR-1a down-regulates under sustained agonism in the same way as GHRH-R is less characterized.
- Body-composition claims are extrapolated. The popular bodybuilding narrative ascribes specific body-composition effects to ipamorelin. The published literature documents GH release and IGF-1 elevation; the body-composition translation is downstream inference, not direct evidence.
How a careful researcher orders ipamorelin
- HPLC + LC-MS per lot. The pentapeptide is small enough that synthesis is reliable, but mass-spec confirmation at the expected 711.85 Da monoisotopic should still appear on the COA.
- Storage at -20°C, light-protected. The histidine and tryptophan-class residues (D-2-Nal) are oxidation-sensitive.
- Bacteriostatic water reconstitution, refrigerated 2–8°C. Stable for ~30 days reconstituted per typical literature protocol.
X Factor ships HPLC + LC-MS on every ipamorelin lot. See the public COA library.
References
- Raun K et al., 1998 — Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol.
- Smith RG et al., 1999 — Peptidomimetic regulation of growth hormone secretion, Endocr Rev.
- Andersen NB et al., 2001 — Selectivity of ipamorelin for GH release versus prolactin and ACTH, J Pept Res.
- Bowers CY, 2004 — Unnatural growth hormone-releasing peptide begets natural ghrelin, J Clin Endocrinol Metab.
- Mathieson MD et al., 2010 — GHSR-1a / GHRH-R synergy in somatotrope GH release, Mol Endocrinol.
- Kojima M et al., 1999 — Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature.
Research use only. Not medical advice. Ipamorelin is not approved by the FDA for any human or veterinary use. Citations are linked directly to PubMed.